Tetra Announces $40M to Advance BPN14770 for FXS and Alzheimer’s Disease

December 19, 2018

Tetra conducted a Phase 2 study of BPN14770 in adults with Fragile X Syndrome. This clinical trial was made possible by early work with the FRAXA-DVI and over $200,000 from FRAXA.

Read More »
Tetra Discovery Partners

Tetra Discovery Partners Initiates Phase 2 Trial of BPN14770 in Fragile X Syndrome

July 10, 2018

This 2-Period Crossover Study of BPN14770 is accepting adults males with Fragile X syndrome at Rush University Medical Center in Chicago. Principal Investigator of the study is Elizabeth Berry-Kravis, MD, PhD.
A selective inhibitor of the phosphodiesterase type-4D (PDE4D), BPN14770 has shown the ability to improve the quality of connections between neurons and to improve multiple behavioral outcomes in the Fragile X mouse model.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (40)